Genmab announced it will terminate clinical development of acasunlimab, a bispecific antibody previously co-developed with BioNTech. The decision follows BioNTech’s exit from the asset last year and represents a formal wind-down of the program at Genmab. Acasunlimab was positioned for lung cancer indications; Genmab’s move removes a late-stage clinical candidate from its oncology pipeline and will affect R&D prioritization. The company will need to determine whether any translational data or biomarker insights from the acasunlimab program can be redeployed into other bispecific or combination strategies.